Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been assigned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $58.4118.

A number of brokerages have recently issued reports on RARE. Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Morgan Stanley upped their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. Cantor Fitzgerald lifted their price objective on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 4,653 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the transaction, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director directly owned 21,095 shares in the company, valued at $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 19,319 shares of company stock worth $476,837 over the last ninety days. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB lifted its stake in shares of Ultragenyx Pharmaceutical by 17.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 39,523 shares of the biopharmaceutical company’s stock worth $1,320,000 after buying an additional 6,000 shares during the last quarter. GAMMA Investing LLC grew its stake in Ultragenyx Pharmaceutical by 149.5% in the 2nd quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,150 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $52,000. Versant Capital Management Inc raised its holdings in Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares during the period. Finally, Parallel Advisors LLC lifted its position in Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $33.82 on Monday. The company has a market cap of $3.33 billion, a price-to-earnings ratio of -5.54 and a beta of 0.31. The firm has a 50-day moving average of $26.71 and a 200-day moving average of $24.50. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue was down 2.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.57) EPS. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical will post -4.53 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.